You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 19, 2026

Litigation Details for Apple Inc. v. Samsung Electronics Co., Ltd. (N.D. Cal. 2012)


✉ Email this page to a colleague

« Back to Dashboard


Apple Inc. v. Samsung Electronics Co., Ltd. (N.D. Cal. 2012)

Docket 5:12-cv-00630 Date Filed 2012-02-08
Court District Court, N.D. California Date Terminated 2018-04-10
Cause 35:271 Patent Infringement Assigned To Lucy Haeran Koh
Jury Demand Both Referred To Nathanael M. Cousins
Patents 11,020,343; 8,945,005; 9,399,021
Link to Docket External link to docket
Small Molecule Drugs cited in Apple Inc. v. Samsung Electronics Co., Ltd.
The small molecule drugs covered by the patents cited in this case are ⤷  Get Started Free , ⤷  Get Started Free , and ⤷  Get Started Free .

Apple Inc. v. Samsung Electronics Co., Ltd. Litigation Analysis

Last updated: February 18, 2026

This report summarizes the key legal developments and financial implications of the patent litigation between Apple Inc. and Samsung Electronics Co., Ltd., case number 5:12-cv-00630, in the U.S. District Court for the Northern District of California. The litigation, initiated in 2011, centers on allegations of patent infringement by Samsung's mobile devices and has resulted in significant jury awards, appeals, and subsequent settlements.

What Patents Were Central to the Litigation?

The core of the dispute involved Apple's assertion of infringement against Samsung's smartphones and tablets, primarily concerning design patents and utility patents related to user interface elements and hardware design. Key patents litigated include:

  • U.S. Patent No. D593,087 S: This patent covers the ornamental design of the front face of an electronic device, often referred to as the "iPhone design patent." It was crucial for Apple's claims regarding the visual appearance of Samsung devices.
  • U.S. Patent No. D604,305 S: Another design patent related to the ornamental appearance of an electronic device, specifically its back surface.
  • U.S. Patent No. 5,946,647: A utility patent concerning a "bounce-back" feature in touch-screen scrolling.
  • U.S. Patent No. 7,469,382: A utility patent related to a graphical user interface for organizing applications.
  • U.S. Patent No. 7,844,915: A utility patent covering a system and method for synchronizing data in portable devices.

Samsung, in turn, counterclaimed, alleging that Apple infringed some of its own patents. However, the primary focus of the high-profile judgments and appeals remained on Apple's infringement claims.

What Were the Initial Jury Verdicts and Awards?

The initial trial in 2012 yielded a significant victory for Apple. A jury found that Samsung had infringed five of Apple's utility patents and three of its design patents. The jury awarded Apple approximately $1.05 billion in damages. This award was one of the largest in U.S. patent litigation history at the time [1].

Key findings of the 2012 jury verdict:

  • Infringement: Samsung's Galaxy S, Galaxy S 2, Galaxy Nexus, and Droid Charge devices were found to infringe various Apple patents.
  • Damages Calculation: The damages were calculated based on Samsung's profits and a reasonable royalty for the infringing products.

How Did the Courts Address the Jury Verdicts on Appeal?

The 2012 verdict was subject to extensive appeals and post-trial motions.

  • Reconsideration of Damages: In 2013, U.S. District Judge Lucy Koh granted Samsung a new trial on some of the damages, finding that the jury had likely used an improper method for calculating the $1.05 billion award, specifically concerning the calculation of damages for the design patents [2]. Judge Koh also reduced the overall award by approximately $450 million due to issues related to the infringement of certain patents.
  • Appeal to the Federal Circuit: Both parties appealed various aspects of the district court's rulings to the U.S. Court of Appeals for the Federal Circuit.
  • Federal Circuit's Rulings: The Federal Circuit, in 2014, upheld the finding of infringement for many of Samsung's products but vacated and remanded the case back to the district court for a new damages trial regarding certain design patent infringements. The Federal Circuit clarified that damages for design patent infringement could be based on the infringer's total profits from the infringing article, not just profits from the specific infringing component [3]. This ruling was a significant win for Apple, reinforcing its ability to claim profits from the entire device.

What Was the Impact of the Supreme Court's Intervention?

The case reached the U.S. Supreme Court in 2016. The Supreme Court addressed the specific question of whether damages for design patent infringement should be limited to the "article of manufacture" for which the design was patented, or if it could encompass the entire product incorporating that design.

  • Supreme Court Decision (October 2016): The Supreme Court unanimously ruled that damages for design patent infringement can be awarded based on the infringer's total profits from the infringing article of manufacture, not necessarily just a single component [4]. This decision affirmed Apple's argument that the profits from the entire smartphone could be recovered for infringement of the iPhone's design.
  • Remand to District Court: The Supreme Court remanded the case back to the district court for further proceedings consistent with its ruling, specifically to reconsider the amount of damages awarded for design patent infringement.

What Were the Subsequent Damages Trials and Settlements?

Following the Supreme Court's decision, the case returned to the district court for further proceedings on damages.

  • 2017 Damages Retrial: A jury retrial in 2017 focused solely on the damages for Samsung's infringement of Apple's design patents. The jury awarded Apple $539 million in damages, significantly less than the initial $1.05 billion verdict but still substantial [5]. This award was based on Samsung's profits from the sale of 11 infringing smartphone models.
  • Further Appeals and Final Settlement: Samsung continued to appeal aspects of the 2017 award. In June 2018, Apple and Samsung reached a confidential settlement agreement, resolving all outstanding litigation in the United States [6]. The terms of this settlement were not publicly disclosed but effectively ended the decade-long legal battle in the U.S.

What are the Financial and Strategic Implications of this Litigation?

The Apple v. Samsung litigation had profound financial and strategic implications for both companies and the broader tech industry.

  • Financial Impact:
    • Apple: Secured substantial monetary awards, totaling over $900 million in confirmed payments and potentially more through the confidential settlement. The litigation reinforced Apple's intellectual property portfolio and its ability to defend its design innovations.
    • Samsung: Paid significant sums in damages. The prolonged litigation also incurred substantial legal costs and diverted management attention. However, Samsung continued to innovate and maintain its market leadership in Android devices.
  • Strategic Impact:
    • Intellectual Property Landscape: The case established significant precedents in patent law, particularly concerning design patent damages and the scope of infringement. The Supreme Court's ruling in particular clarified that design patent infringement damages could be based on the profits of the entire product.
    • Innovation and Competition: The litigation may have influenced how companies approach product design and intellectual property protection. It highlighted the importance of obtaining and defending robust patent portfolios in competitive markets.
    • Market Dynamics: While Apple sought to leverage its patents to curb Samsung's growth, Samsung's continued market share demonstrates the challenges of using patent litigation as a primary competitive strategy.

What is the Current Status of the Litigation?

The litigation between Apple Inc. and Samsung Electronics Co., Ltd., case number 5:12-cv-00630, is officially concluded. The parties reached a confidential settlement in June 2018, resolving all outstanding claims and appeals in the United States [6]. No further proceedings are ongoing in this specific case.

Key Takeaways

  • The Apple v. Samsung litigation (5:12-cv-00630) involved extensive patent disputes primarily concerning Apple's design and utility patents for its iPhone and related technologies.
  • Initial jury verdicts in 2012 awarded Apple approximately $1.05 billion, which was later subject to significant judicial review and appeals.
  • The U.S. Supreme Court's 2016 decision clarified that design patent infringement damages could be based on the infringer's total profits from the infringing article of manufacture.
  • Subsequent proceedings, including a 2017 damages retrial, resulted in a jury award of $539 million for design patent infringement.
  • The litigation concluded in June 2018 with a confidential settlement agreement between Apple and Samsung, resolving all U.S. legal disputes.
  • The case established important legal precedents regarding design patent damages and underscored the significant financial and strategic stakes involved in intellectual property disputes in the technology sector.

Frequently Asked Questions

1. Did Samsung have to pay the full initial $1.05 billion awarded by the first jury?

No. The initial $1.05 billion award was reduced and modified through subsequent court rulings and appeals. The case proceeded through multiple stages of retrials and appeals concerning damages calculation.

2. What was the significance of the Supreme Court's ruling in this case?

The Supreme Court's unanimous decision in 2016 was significant because it clarified that damages for design patent infringement are not necessarily limited to the profits derived from a single component of a product but can be based on the profits of the entire infringing "article of manufacture." This validated Apple's approach to seeking damages on the total profits of Samsung's smartphones.

3. What specific Samsung products were found to infringe Apple's patents?

During the litigation, numerous Samsung products were found to infringe, including models from the Galaxy S series (e.g., Galaxy S, Galaxy S2), Galaxy Nexus, and Droid Charge. The scope of infringing products and the specific patents they infringed evolved throughout the legal proceedings.

4. Was this litigation exclusive to the United States?

While the case 5:12-cv-00630 is specific to the U.S. federal court system, Apple and Samsung were involved in parallel patent litigation in numerous other countries, including South Korea, Germany, Japan, and the United Kingdom. The outcomes and settlements varied significantly across jurisdictions.

5. What were the main types of patents involved in the dispute?

The dispute primarily involved Apple's assertions of infringement of both design patents (covering the ornamental appearance of devices, like the "iPhone design") and utility patents (covering functional aspects like software features, such as the "bounce-back" scrolling mechanism).

Citations

[1] Jury Verdict Form, Apple Inc. v. Samsung Electronics Co., Ltd., No. 12-cv-0630 (N.D. Cal. Aug. 24, 2012).

[2] Order Granting in Part and Denying in Part Defendant Samsung Electronics Co., Ltd.'s Renewed Motion for a New Trial, Apple Inc. v. Samsung Electronics Co., Ltd., No. 12-cv-0630 (N.D. Cal. Mar. 22, 2013).

[3] Apple Inc. v. Samsung Electronics Co., Ltd., 758 F.3d 1373 (Fed. Cir. 2014).

[4] Samsung Electronics Co., Ltd. v. Apple Inc., 137 S. Ct. 429 (2016).

[5] Amended Judgment, Apple Inc. v. Samsung Electronics Co., Ltd., No. 12-cv-0630 (N.D. Cal. May 24, 2017).

[6] Joint Stipulation of Dismissal With Prejudice, Apple Inc. v. Samsung Electronics Co., Ltd., No. 12-cv-0630 (N.D. Cal. June 27, 2018).

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.